Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

MLA

Keunchil Park, et al. “Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 13, Apr. 2018, pp. 576–84. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.11.131.

APA

Keunchil Park, Egbert F. Smit, Christos Chouaid, Dong Wan Kim, Emin Avsar, Edward B. Garon, Enriqueta Felip, Leena Gandhi, Lecia V. Sequist, Paal Brunsvig, Enric Carcereny, Harry J.M. Groen, Benjamin Besse, Quincy Chu, Mikhail Akimov, Sebastian Szpakowski, Sang-We Kim, & Fabrice Barlesi. (2018). Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 576–584. https://doi.org/10.1016/j.jtho.2017.11.131

Chicago

Keunchil Park, Egbert F. Smit, Christos Chouaid, Dong Wan Kim, Emin Avsar, Edward B. Garon, Enriqueta Felip, et al. 2018. “Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer.” Journal of Thoracic Oncology 13 (April): 576–84. doi:10.1016/j.jtho.2017.11.131.